Camzyos (mavacamten) Letter of Medical Necessity
Camzyos (mavacamten) is the first FDA-approved cardiac myosin inhibitor, specifically indicated for obstructive HCM. It requires enrollment in the CAMZYOS REMS Program due to the risk of systolic dysfunction. PA review is strict: echocardiographic confirmation of LVOT obstruction, NYHA class documentation, LVEF ≥55%, and REMS compliance are universally required. Denials without these elements are nearly automatic.
FDA-Approved Indications
- ● obstructive hypertrophic cardiomyopathy (oHCM) in adults with NYHA Class II–III symptoms to improve functional capacity and symptoms
Why Camzyos Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. oHCM diagnosis not confirmed by echocardiogram (LVOT gradient <30 mmHg at rest or ≤50 mmHg with provocation)
- 2. NYHA functional class not documented (requires Class II or III)
- 3. REMS enrollment not completed (CAMZYOS REMS Program mandatory)
- 4. Prescriber not REMS-certified
- 5. Beta-blocker or calcium channel blocker trial not documented
- 6. Baseline LVEF <55% — absolute contraindication per labeling
- 7. Echocardiogram within required timeframe not provided
What to Include in a Camzyos Letter of Medical Necessity
Document obstructive HCM diagnosis confirmed by echocardiography (resting LVOT gradient ≥30 mmHg or provoked gradient ≥50 mmHg), LVEF ≥55% (contraindicated if <55%), NYHA functional Class II or III symptoms, prior pharmacotherapy trials (beta-blocker and/or verapamil/diltiazem) with documented inadequate response or intolerance, CAMZYOS REMS Program enrollment for both prescriber and dispensing pharmacy, absence of concomitant strong CYP3A4/CYP2C19 inhibitors (drug-drug interaction requires monitoring), and baseline echocardiogram within 6 months of initiation.
Key clinical evidence to cite:
- ✓ EXPLORER-HCM Phase 3 trial — significant improvement in peak VO2, NYHA class, and LVOT gradient vs placebo
- ✓ VALOR-HCM — significant reduction in septal reduction therapy (SRT) referrals at 16 weeks (17.9% vs 76.7% meeting SRT criteria)
- ✓ First FDA-approved cardiac myosin inhibitor — disease-modifying mechanism targeting the root cause of oHCM hypercontractility
Relevant guidelines:
- 📖 AHA/ACC 2020 HCM Guidelines
- 📖 AHA/ACC 2022 HCM Focused Update (Class IIa for oHCM)
- 📖 HCMA Clinical Guidelines
Camzyos Prior Authorization Criteria
Standard criteria across major US payers for Camzyos. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Beta-blocker or calcium channel blocker trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Camzyos
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Camzyos Prior Authorization FAQ
Why was my Camzyos prior authorization denied?
The most common denial reasons for Camzyos are: oHCM diagnosis not confirmed by echocardiogram (LVOT gradient <30 mmHg at rest or ≤50 mmHg with provocation); NYHA functional class not documented (requires Class II or III); REMS enrollment not completed (CAMZYOS REMS Program mandatory); Prescriber not REMS-certified; Beta-blocker or calcium channel blocker trial not documented; Baseline LVEF <55% — absolute contraindication per labeling; Echocardiogram within required timeframe not provided.
What should a Camzyos Letter of Medical Necessity include?
Document obstructive HCM diagnosis confirmed by echocardiography (resting LVOT gradient ≥30 mmHg or provoked gradient ≥50 mmHg), LVEF ≥55% (contraindicated if <55%), NYHA functional Class II or III symptoms, prior pharmacotherapy trials (beta-blocker and/or verapamil/diltiazem) with documented inadequate response or intolerance, CAMZYOS REMS Program enrollment for both prescriber and dispensing pharmacy, absence of concomitant strong CYP3A4/CYP2C19 inhibitors (drug-drug interaction requires monitoring), and baseline echocardiogram within 6 months of initiation.
Which payers cover Camzyos?
Camzyos is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B/D, though formulary tier and prior authorization criteria vary.